The National Medical Insurance Administration determines the rules for renewing contracts with volume purchases

On November 4, the official website of the National Medical Insurance Administration issued the "Notice on Doing a Good Job in Continuing Work after the Expiry of the National Organizational Drug Centralized Purchase Agreement
.
" The "Notice" pointed out that, in principle, all countries should continue to carry out centralized procurement of drugs after the expiry of the centralized procurement agreement, and it is not allowed to "negotiate only on price and not carry the quantity
.
" Holders of the original research drugs, reference preparations, and drug marketing licenses that have passed the quality and efficacy consistency evaluation of generic drugs can all participate
.
All provinces, autonomous regions, municipalities directly under the Central Government, and Xinjiang Production and Construction Corps Medical Insurance Bureau: To implement the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized and Mass Procurement of Drugs" (Guobanfa [2021] No.
2), consolidate the national organization The results of the reform of centralized drug procurement have realized the smooth continuation of the procurement agreement after the expiration of the period
.
The relevant work requirements are hereby notified as follows .
1.
Attach great importance to the continuation work after the expiration of the agreement.
The smooth implementation of the continuation work after the expiration of the state-organized centralized drug procurement agreement (hereinafter referred to as the "continuation work") is to implement the decision and deployment of the Party Central Committee and the State Council on the reform of the centralized drug procurement system.
An important link to promote the normalized and institutionalized operation of centralized and volume procurement
.
All localities should fully understand the importance of doing this work well, conscientiously unify their thoughts and actions into the decision-making and deployment of the Party Central Committee, adhere to the people-centered principle, adhere to the principle of "integration of recruitment and procurement, and linkage of quantity and price", and align the direction of reform.
, Focusing on stabilizing market expectations, stabilizing price levels, and stabilizing clinical use, with provinces (autonomous regions, municipalities directly under the Central Government and Xinjiang Production and Construction Corps) or inter-provincial alliance as the unit, comply with laws and regulations, carry out continuity work steadily, and guide the society to form long-term stable expectations
.
2.
Carry out the connection work carefully (1) Persist in purchasing in quantity
.
In principle, all national organizations should continue to carry out centralized procurement with quantity after the expiration of the agreement on centralized procurement of medicines, and it is not allowed to "negotiate only without quantity"
.
Holders of the original research drugs, reference preparations, and drug marketing licenses that have passed the quality and efficacy consistency evaluation of generic drugs can all participate
.
The medical institution shall report the demand for the drugs to be purchased in combination with the actual use volume, clinical use status and medical technology progress of the previous year.

.
The medical insurance department summarizes the total demand submitted by the medical institution, and determines the agreed purchase amount based on the proportion of the amount.
In principle, it shall not be less than the agreed purchase amount of the previous year
.
For medical institutions whose reporting requirements are significantly lower than the previous year's purchases, they should be required to provide explanations and increase supervision over their purchases
.
The rules for the allocation of procurement volume should be clearly agreed in advance to ensure that the agreed procurement volume is allocated to each selected company and each medical institution
.
(2) Carry out continuation by classification
.
Focusing on maintaining the stability of the market and clinical medication, comprehensively considering the various factors of enterprises and products, and determining the selected enterprises and prices through inquiry, bidding, and comprehensive evaluation
.
1.
For the varieties selected in the previous round of centralized procurement, in principle, the inquiry will be carried out on the basis of a stable price level and clinical use
.
If the price in the last round of the province where the province is selected is not higher than 1.
5 times the lowest price in the country, the price in the last round of the province is used as the baseline to inquire all eligible companies; the price in the last round of the province where the price is higher than the lowest price in the country If the price is 1.
5 times, an inquiry will be conducted to all eligible enterprises based on the baseline not higher than 1.
5 times the lowest selected price in the country
.
The upper limit of the inquiry is the highest selected price in the country in the previous round
.
According to the company's willingness to quote, combined with the results of the comprehensive evaluation of the company and its products, the selected company and the price of the selected company can be determined
.
2.
If the inquiry is unsuccessful, or the result of the selection was produced in the last round of centralized procurement, or the actual sales price of the non-selected products in the current market is significantly lower than the lowest selected price in the province in the previous round of centralized procurement and there is actual supply, The selected companies and the selected prices can be reproduced through bidding
.
Provinces with large demand or high supply guarantee requirements are encouraged to select the same product from multiple companies, and the price difference between different selected companies should be fair and reasonable
.
According to the principle of quantity-price linkage, clarify the agreed procurement volume of each selected company
.
The period of the procurement agreement can be determined by referring to the relevant rules of the national organization of centralized drug procurement, and the procurement cycle can be adjusted appropriately to gradually unify the execution time of different centralized procurement batches.

.
Encourage the comprehensive evaluation of the company's supply, contract performance, product quality, and clinical response
.
(3) Strengthen credit and performance evaluation
.
Integrate credit evaluation and contract performance into the main links of the continuation rules, so that it can play a substantive role in the enterprise's application qualification, selection qualification, selection order, and supply area selection
.
Where a comprehensive evaluation method is used to determine the selected enterprise, each province should incorporate the enterprise’s credit evaluation and contract performance into the comprehensive evaluation factors and give it a higher weight
.
If the comprehensive evaluation has not been adopted yet, the price of medicines and the credit evaluation of recruitment and procurement should be considered as one of the important conditions for the shortlisting of the enterprise
.
Under the same circumstances, the enterprise with a better credit evaluation shall be selected first .
For companies that have been selected in the previous round, if the comprehensive evaluation results or the credit and contract performance are good, they can be given priority in the succession work; if the credit and contract performance are poor, they should be punished in the succession rules
.
If the applicant enterprise is included in the “violation list” by the National Organization for Drug Purchasing Office or recognized as untrustworthy to varying degrees by the province where it is located, it may take measures such as shifting the selected order, reducing the proportion of the quantity, and reducing the supply area according to the regulations, until Suspend its eligibility to participate in the succession
.
(4) Improve supporting policies
.
Continue to implement the prepayment of medical insurance funds to reduce the pressure on medical institutions to pay back
.
We will improve the rules for centrally sourced varieties to be linked to the Internet, and further coordinate the medical insurance payment standards and the selected prices to effectively enhance the patient's sense of acquisition
.
(5) Strengthen the supervision of contract performance
.
Establish and improve the information traceability system of selected drugs to ensure that the selected drugs can be traced in the whole process of production and circulation
.
Carry out monitoring and evaluation on the supply, credit and other aspects of the selected enterprises, consolidate the performance responsibilities, and apply the evaluation results to future centralized procurement work
.
Regularly monitor the purchase, use and payment return of medical institutions to ensure that medical institutions use rationally, give priority to the use of selected products and promptly return payments
.
3.
Strengthen the organization and implementation of medical security departments in all regions should effectively assume the responsibility of overall coordination and supervision, refinement and improvement of the implementation plan in the region, strengthen policy coordination and work cooperation with relevant departments, and carry out continuation work in a timely manner.
Major issues should be reported to the state in time Security Bureau report
.
The National Organization for Pharmaceutical Joint Procurement Office continued to do a good job of daily monitoring and analysis, and urged the implementation of procurement results
.
Hereby inform
.
Office of the National Medical Security Administration November 3, 2021